CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Ionis Pharmaceuticals, Inc. - IONS CFD

42.13
1.01%
0.22
Low: 41.36
High: 42.32
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.22
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Ionis Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 41.71
Open* 41.5
1-Year Change* 14.96%
Day's Range* 41.36 - 42.32
52 wk Range 32.69-48.82
Average Volume (10 days) 1.48M
Average Volume (3 months) 21.22M
Market Cap 5.97B
P/E Ratio -100.00K
Shares Outstanding 143.09M
Revenue 575.97M
EPS -2.31
Dividend (Yield %) N/A
Beta 0.52
Next Earnings Date Aug 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 5, 2023 42.13 0.89 2.16% 41.24 42.37 41.03
Jun 2, 2023 41.71 0.52 1.26% 41.19 43.27 41.08
Jun 1, 2023 42.94 3.49 8.85% 39.45 43.03 39.45
May 31, 2023 40.73 0.71 1.77% 40.02 41.21 39.74
May 30, 2023 40.51 0.26 0.65% 40.25 41.55 39.84
May 26, 2023 40.60 2.27 5.92% 38.33 40.83 38.33
May 25, 2023 39.13 -0.39 -0.99% 39.52 41.57 38.89
May 24, 2023 41.24 -0.58 -1.39% 41.82 42.47 41.09
May 23, 2023 42.16 1.62 4.00% 40.54 43.42 40.54
May 22, 2023 40.61 1.75 4.50% 38.86 40.81 37.78
May 19, 2023 39.02 3.61 10.19% 35.41 39.31 35.41
May 18, 2023 36.58 2.03 5.88% 34.55 36.70 34.55
May 17, 2023 36.13 1.42 4.09% 34.71 36.29 34.70
May 16, 2023 35.79 0.93 2.67% 34.86 35.96 34.81
May 15, 2023 36.09 0.68 1.92% 35.41 36.39 34.70
May 12, 2023 35.38 0.05 0.14% 35.33 35.68 35.16
May 11, 2023 35.48 0.79 2.28% 34.69 35.72 34.69
May 10, 2023 35.69 0.86 2.47% 34.83 36.65 34.83
May 9, 2023 35.57 0.81 2.33% 34.76 36.18 34.51
May 8, 2023 35.18 -0.28 -0.79% 35.46 35.88 34.81

Ionis Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, June 12, 2023

Time (UTC)

16:20

Country

US

Event

Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference

Forecast

-

Previous

-
Monday, August 7, 2023

Time (UTC)

12:30

Country

US

Event

Q2 2023 Ionis Pharmaceuticals Inc Earnings Release
Q2 2023 Ionis Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Tuesday, November 7, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Ionis Pharmaceuticals Inc Earnings Release
Q3 2023 Ionis Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 587.367 810.456 729.264 1122.6 599.674
Revenue 587.367 810.456 729.264 1122.6 599.674
Cost of Revenue, Total 14.116 10.842 11.947 4.384 1.82
Gross Profit 573.251 799.614 717.317 1118.21 597.854
Total Operating Expense 997.558 849.269 901.346 822.912 661.046
Selling/General/Admin. Expenses, Total 150.295 170.947 332.222 286.644 244.622
Research & Development 833.147 634.953 526.877 465.688 414.604
Unusual Expense (Income) 32.527 30.3 66.196 0
Operating Income -410.191 -38.813 -172.082 299.687 -61.372
Interest Income (Expense), Net Non-Operating 9.876 10.798 37.592 39.765 -14.602
Other, Net -7.274 -1.133 -0.062 -0.686 -0.182
Net Income Before Taxes -257.985 -29.148 -134.552 338.766 -76.156
Net Income After Taxes -269.722 -28.597 -479.743 287.259 -117.115
Minority Interest 0 0 35.48 -9.116 58.756
Net Income Before Extra. Items -269.722 -28.597 -444.263 278.143 -58.359
Net Income -269.722 -28.597 -444.263 278.143 273.741
Income Available to Common Excl. Extra. Items -269.722 -28.597 -444.263 278.143 -58.359
Income Available to Common Incl. Extra. Items -269.722 -28.597 -444.263 278.143 273.741
Dilution Adjustment 0
Diluted Net Income -269.722 -28.597 -444.263 278.143 273.741
Diluted Weighted Average Shares 141.848 141.021 139.612 153.164 134.056
Diluted EPS Excluding Extraordinary Items -1.90149 -0.20279 -3.18213 1.81598 -0.43533
Diluted Normalized EPS -2.58703 -0.05286 -3.04106 2.18246 -0.43533
Total Extraordinary Items 332.1
Gain (Loss) on Sale of Assets 149.604
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 130.524 151.889 159.767 133.791 141.919
Revenue 130.524 151.889 159.767 133.791 141.919
Cost of Revenue, Total 1.343 3.686 1.515 4.745 4.17
Gross Profit 129.181 148.203 158.252 129.046 137.749
Total Operating Expense 244.672 359.908 218.921 219.305 199.423
Selling/General/Admin. Expenses, Total 45.516 47.95 34.416 33.802 34.127
Research & Development 197.813 308.272 182.99 180.758 161.126
Operating Income -114.148 -208.019 -59.154 -85.514 -57.504
Interest Income (Expense), Net Non-Operating 16.49 13.436 7.732 -5.064 -6.754
Other, Net -15.285 0.649 4.713 -12.297 0.187
Net Income Before Taxes -112.943 -44.33 -46.709 -102.875 -64.071
Net Income After Taxes -124.323 -52.43 -46.992 -105.135 -65.165
Minority Interest 0
Net Income Before Extra. Items -124.323 -52.43 -46.992 -105.135 -65.165
Net Income -124.323 -52.43 -46.992 -105.135 -65.165
Income Available to Common Excl. Extra. Items -124.323 -52.43 -46.992 -105.135 -65.165
Income Available to Common Incl. Extra. Items -124.323 -52.43 -46.992 -105.135 -65.165
Diluted Net Income -124.323 -52.43 -46.992 -105.135 -65.165
Diluted Weighted Average Shares 142.735 142.046 141.95 141.794 141.599
Diluted EPS Excluding Extraordinary Items -0.87101 -0.36911 -0.33105 -0.74146 -0.46021
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.87101 -1.05369 -0.33105 -0.74146 -0.46021
Unusual Expense (Income)
Gain (Loss) on Sale of Assets 149.604
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2202.69 2345.05 2130.71 2720.6 2207.89
Cash and Short Term Investments 1986.87 2114.97 1892.38 2499.54 2084.07
Cash & Equivalents 276.472 869.191 397.664 683.287 278.82
Short Term Investments 1710.4 1245.78 1494.71 1816.26 1805.25
Total Receivables, Net 25.538 61.896 76.204 63.034 12.759
Accounts Receivable - Trade, Net 25.538 61.896 76.204 63.034 12.759
Total Inventory 22.033 24.806 21.965 18.18 8.582
Other Current Assets, Total 168.254 143.374 140.163 139.839 102.473
Total Assets 2533.88 2611.69 2389.75 3233.11 2667.78
Property/Plant/Equipment, Total - Net 255.838 196.069 181.077 166.251 132.16
Property/Plant/Equipment, Total - Gross 343.554 298.722 240.264 193.634
Accumulated Depreciation, Total -87.716 -102.653 -74.013 -61.474
Intangibles, Net 29.005 27.937 25.674 24.032
Other Long Term Assets, Total 75.344 41.567 50.034 320.59 303.706
Total Current Liabilities 311.561 240.55 598.898 273.005 280.294
Accounts Payable 17.921 11.904 17.199 16.067 28.66
Accrued Expenses 196.494 129.97 155.889 106.152 77.629
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.32 0.926 316.11 13.749
Other Current Liabilities, Total 96.826 97.75 109.7 150.786 160.256
Total Liabilities 1960.99 1839.95 1646.47 1762.02 1619.7
Total Long Term Debt 1182.72 1228.02 623.529 770.3 632.971
Long Term Debt 1182.72 1228.02 623.529 770.3 632.971
Capital Lease Obligations
Other Liabilities, Total 466.709 371.379 424.046 505.26 567.359
Total Equity 572.887 771.737 743.282 1471.09 1048.08
Common Stock 0.142 0.141 0.14 0.14 0.138
Additional Paid-In Capital 2059.85 1964.17 1895.52 2203.78 2047.25
Retained Earnings (Accumulated Deficit) -1429.62 -1159.9 -1131.31 -707.534 -967.293
Other Equity, Total -57.48 -32.668 -21.071 -25.29 -32.016
Total Liabilities & Shareholders’ Equity 2533.88 2611.69 2389.75 3233.11 2667.78
Total Common Shares Outstanding 142.058 141.21 140.366 140.34 137.929
Minority Interest 213.453 139.081
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 2542.62 2202.69 2152.13 2191.15 2253.12
Cash and Short Term Investments 2346.78 1986.87 1981.66 2021.83 2052.39
Cash & Equivalents 309.031 276.472 314.993 521.917 542.513
Short Term Investments 2037.75 1710.4 1666.67 1499.91 1509.88
Total Receivables, Net 13.914 25.538 6.645 6.751 26.122
Accounts Receivable - Trade, Net 13.914 25.538 6.645 6.751 26.122
Total Inventory 22.2 22.033 20.645 19.811 24.032
Other Current Assets, Total 159.724 168.254 143.173 142.759 150.577
Total Assets 2885.22 2533.88 2421.97 2456.13 2519.09
Property/Plant/Equipment, Total - Net 264.306 255.838 180.806 177.015 177.724
Intangibles, Net 29.605 29.054 29.295
Other Long Term Assets, Total 78.296 75.344 59.434 58.916 58.949
Total Current Liabilities 259.221 311.561 283.454 267.811 228.45
Accounts Payable 10.499 17.921 20.545 10.351 16.125
Accrued Expenses 130.862 189.279 158.412 159.321 115.781
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 8.239 7.535 4.97 4.732 4.206
Other Current Liabilities, Total 109.621 96.826 99.527 93.407 92.338
Total Liabilities 2398.65 1960.99 1827.61 1831.41 1809.52
Total Long Term Debt 1184.38 1182.72 1249.5 1248.4 1247.93
Long Term Debt 1184.38 1182.72 1249.5 1248.4 1247.93
Other Liabilities, Total 955.054 466.709 294.656 315.196 333.138
Total Equity 486.57 572.887 594.361 624.726 709.574
Common Stock 0.143 0.142 0.142 0.142 0.142
Additional Paid-In Capital 2089.36 2059.85 2034.55 2008.79 1983.08
Retained Earnings (Accumulated Deficit) -1553.95 -1429.62 -1377.19 -1330.2 -1225.07
Other Equity, Total -48.983 -57.48 -63.14 -54.007 -48.578
Total Liabilities & Shareholders’ Equity 2885.22 2533.88 2421.97 2456.13 2519.09
Total Common Shares Outstanding 143.023 142.058 142.017 141.831 141.753
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -269.722 -28.597 -479.743 287.259 214.985
Cash From Operating Activities -274.37 30.799 35.892 345.627 602.906
Cash From Operating Activities 14.328 15.487 13.365 12.54 10.706
Amortization 2.415 2.352 2.064 1.912 1.822
Deferred Taxes 0 0 341.729 0.911 -290.516
Non-Cash Items -28.962 155.375 232.032 211.806 166.484
Cash Interest Paid 2.898 4.778 6.247 9.87 9.592
Changes in Working Capital 7.571 -113.818 -73.555 -168.801 499.425
Cash From Investing Activities -262.636 194.906 274.477 -41.274 -929.563
Capital Expenditures -15.721 -11.955 -35.12 -30.905 -13.608
Other Investing Cash Flow Items, Total -246.915 206.861 309.597 -10.369 -915.955
Cash From Financing Activities -55.295 245.933 -596.609 100.021 475.865
Financing Cash Flow Items -10.982 -168.954 -558.097 -138.354 0
Issuance (Retirement) of Stock, Net 6.373 101.317 -38.512 141.375 475.865
Issuance (Retirement) of Debt, Net -50.686 313.57 0 97 0
Net Change in Cash -592.719 471.527 -285.623 404.467 149.19
Cash Taxes Paid 5.01 0.038 25.855 9.041 0
Foreign Exchange Effects -0.418 -0.111 0.617 0.093 -0.018
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -124.323 -269.722 -217.292 -170.3 -65.165
Cash From Operating Activities -133.992 -274.37 -74.175 -49.746 -31.65
Cash From Operating Activities 2.604 14.328 11.301 7.484 3.701
Amortization 0.607 2.415 1.805 1.197 0.592
Deferred Taxes 0
Non-Cash Items 42.124 -28.962 91.563 64.125 32.983
Cash Taxes Paid 0.293 5.01 0.002 0.002 0.002
Cash Interest Paid 0.089 2.898 2.204 1.544 0.594
Changes in Working Capital -55.004 7.571 38.448 47.748 -3.761
Cash From Investing Activities -325.64 -262.636 -474.783 -290.853 -287.549
Capital Expenditures -10.472 -15.721 -11.582 -6.04 -2.705
Other Investing Cash Flow Items, Total -315.168 -246.915 -463.201 -284.813 -284.844
Cash From Financing Activities 492.087 -55.295 -4.276 -6.11 -7.325
Financing Cash Flow Items 489.566 -10.982 -10.217 -9.572 -9.173
Issuance (Retirement) of Stock, Net 2.56 6.373 6.03 3.462 1.848
Foreign Exchange Effects 0.104 -0.418 -0.964 -0.565 -0.154
Net Change in Cash 32.559 -592.719 -554.198 -347.274 -326.678
Issuance (Retirement) of Debt, Net -0.039 -50.686 -0.089 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 14.9808 21436334 128815 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.7482 13948885 429096 2023-03-31 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 9.1298 13064047 1385788 2023-03-31 MED
Bellevue Asset Management AG Investment Advisor 6.6474 9511900 -232000 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.9323 7057705 -70015 2023-03-31 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 3.7679 5391581 -34061 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.8432 4068334 -150395 2023-03-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.6508 3793044 -359563 2023-03-31 LOW
Tweedy, Browne Company LLC Investment Advisor 2.4747 3541046 -90 2023-03-31 LOW
Deep Track Capital LP Hedge Fund 1.9806 2834069 1628296 2023-03-31 HIGH
ARK Investment Management LLC Investment Advisor 1.843 2637192 -36346 2023-03-31 LOW
BVF Partners L.P. Hedge Fund 1.7896 2560761 1438952 2023-03-31 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.4847 2124500 130900 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4466 2069950 57227 2023-03-31 LOW
Camber Capital Management LP Hedge Fund 1.3453 1925000 0 2023-03-31 MED
First Trust Advisors L.P. Investment Advisor 1.1454 1638943 -141990 2023-03-31 LOW
Macquarie Investment Management Investment Advisor 1.044 1493903 2216 2023-03-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9062 1296647 511086 2022-12-31 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.8291 1186393 -69875 2023-03-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.7778 1113042 739456 2023-03-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Ionis Pharmaceuticals Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry: Biotechnology & Medical Research (NEC)

2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

25,768.55 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

XRP/USD

0.51 Price
+0.490% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00391

Gold

1,961.68 Price
-0.010% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0102%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

14,555.10 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading